22157.jpg
CRISPR Therapies Market Research 2024: Pipeline Analysis, Therapeutic Assessment, Unmet Needs, Impact of Drugs
June 14, 2024 06:15 ET | Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "CRISPR therapies - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "CRISPR Therapies - Pipeline...
CRISPR Technology Market
CRISPR Technology Global Strategic Research Report 2024
June 14, 2024 05:30 ET | Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "CRISPR Technology - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for CRISPR...
PFS image_Caribou Biosciences
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 02, 2024 19:00 ET | Caribou Biosciences, Inc.
-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER...
Caribou_logo.png
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
May 30, 2024 16:01 ET | Caribou Biosciences, Inc.
BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Power of Recursion O
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
May 29, 2024 15:27 ET | Recursion Pharmaceuticals
SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature...
Cytosurge Logo_cyan - RGB.png
Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
May 29, 2024 08:30 ET | Cytosurge AG
CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.
Cover Biotechnology Journal April 2024 - Cytosurge CellEDIT publication
Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
May 29, 2024 02:30 ET | Cytosurge AG
CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.
TOME-Logo-RGB.png
Tome Biosciences Presented Data on its Programmable Genomic Integration Technologies at ASGCT
May 10, 2024 06:00 ET | Tome Biosciences
Tome presented data updates on its programmable genomic integration technologies at ASGCT.
Caribou_logo.png
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024 16:05 ET | Caribou Biosciences, Inc.
-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into...
fulllogo_transparent_nobuffer Aanastra.png
Aanastra Inc to Showcase its Peptide-RNA Therapeutics Technology in Multiple Presentations at the American Society for Gene and Cell Therapies (ASGCT) Annual Meeting 2024
May 02, 2024 06:30 ET | Aanastra Inc
Aanastra showcases its peptide-RNA therapeutics targeting p53, KRAS and BRCA-1 driven cancers, hemophilia A and PCSK9 for hypercholestrolemia at ASGCT